The invention relates to novel crystalline forms of 3-(4-amino-l-oxo-l,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione, including a novel urea cocrystal of 3-(4-amino-l-oxo-l,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; a novel gallic acid cocrystal of 3-(4-amino-l-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; a novel propyl gallate cocrystal of 3-(4-amino-l-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; and a novel L-tartaric acid cocrystal of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione. The preparation and characterization of the novel crystalline forms according to various embodiments of the invention are described. The invention also relates to pharmaceutical compositions containing the novel crystalline forms, and the therapeutic use of the novel crystalline forms.
本发明涉及 3-(4-
氨基-1-氧代-1,3-二氢-异
吲哚-2-基)-
哌啶-2,6-二酮的新型结晶形式,包括 3-(4-
氨基-1-氧代-1,3-二氢-异
吲哚-2-基)-
哌啶-2,6-二酮的新型
脲共晶体;3-(4-
氨基-l-氧代-1,3-二氢-异
吲哚-2-基)-
哌啶-2,6-二酮的新型
没食子酸共晶体; 3-(4-
氨基-l-氧代-1,3-二氢-异
吲哚-2-基)-
哌啶-2,6-二酮的新型
没食子酸丙酯共晶体;以及 3-(4-
氨基-1-氧代-1,3-二氢-异
吲哚-2-基)-
哌啶-2,6-二酮的新型
L-酒石酸共晶体。本发明描述了根据本发明各种实施方案制备的新型晶体的制备和表征。本发明还涉及含有新型结晶形式的药物组合物以及新型结晶形式的治疗用途。